SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
South Korean biopharmaceutical firm Celltrion Inc. will acquire the patent, trademark, and sales rights for 18 brands of Japan's Takeda Pharmaceutical in Asia-Pacific for 332.4 billion won.
The company will pursue the deal through its Singapore-based affiliate, hoping the complete the acquisition by year's end.
The nine markets covered by business rights include South Korea, Thailand, Malaysia, and Australia.
The 18 brands amassed a combined sales of $140 million in Asia-Pacific in 2018.
Celltrion plans to sell the brands through its affiliates Celltrion Pharma and Celltrion Healthcare.
The acquisition not only helps to stabilize the local supply of medication for hypertension, diabetes, and hyperlipidemia but also serves as Celltrion's first significant move in accelerating its push into the global market.
Celltrion had a net income of 298 billion won in 2019, a 17.5 percent surge from the year before.
